Neurovia Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Neurovia General Information

Description

Developer of therapies designed to offer treatment for neurological disorders. The company's therapies have developed a selective thyromimetic agent for the treatment of X-linked adrenoleukodystrophy, enabling X-ALD patients to get treatment for their rare genetic disease.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Corporate Office
  • 1700 Owens Street
  • Suite 525
  • San Francisco, CA 94158
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurovia Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 01-Nov-2018 000.00 Completed Out of Business
1. Early Stage VC (Series A) 25-May-2017 000.00 000.00 000.00 Completed Clinical Trials - Phase 1
To view Neurovia’s complete valuation and funding history, request access »

Neurovia Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00.00 00 00 00 00 00.000
To view Neurovia’s complete cap table history, request access »

Neurovia Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapies designed to offer treatment for neurological disorders. The company's therapies have developed a
Biotechnology
San Francisco, CA
000.00
00000000 00 000.00

000000

dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco
0000000000000
San Diego, CA
00 As of 0000
00000
000000000 00000

000000

adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliq
000000000000000
Mountain View, CA
000 As of 0000
00000
00.000 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Neurovia Competitors (18)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cidara Therapeutics Formerly VC-backed San Diego, CA 00 00000 000000000 00000
Chemocentryx Formerly VC-backed Mountain View, CA 000 00000 000000&0 00000
Lineage Cell Therapeutics Corporation Carlsbad, CA 00 00000 000000000 00000
Regulus Therapeutics Formerly VC-backed San Diego, CA 00 00000 000000000 00000
Biorchestra Venture Capital-Backed Daejeon, South Korea 00 000.00 00000000000 000.00
You’re viewing 5 of 18 competitors. Get the full list »

Neurovia FAQs

  • When was Neurovia founded?

    Neurovia was founded in 2013.

  • Who is the founder of Neurovia?

    Giovanni Ferrara and Thomas Scanlan Ph.D are the founders of Neurovia.

  • Where is Neurovia headquartered?

    Neurovia is headquartered in San Francisco, CA.

  • What industry is Neurovia in?

    Neurovia’s primary industry is Biotechnology.

  • Is Neurovia a private or public company?

    Neurovia is a Private company.

  • What is Neurovia’s current revenue?

    The current revenue for Neurovia is 00000.

  • How much funding has Neurovia raised over time?

    Neurovia has raised $13.9M.

  • Who are Neurovia’s competitors?

    Cidara Therapeutics, Chemocentryx, Lineage Cell Therapeutics, Regulus Therapeutics, and Biorchestra are some of the 18 competitors of Neurovia.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »